Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)

COVID-19 Clinical Trial

— ECMO-VID  

Official title:

Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04341285
• Other study ID #: ECMO-VID
• Status: Withdrawn
• Phase: N/A
• Start date: August 1, 2020
• Est. completion date: May 1, 2022

Study information

• Verified date: June 2020
• Source: University Hospital Tuebingen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit. Control intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias. Duration of intervention per patient: varies, depending on severity of pulmonary compromise Follow-up per patient: Until hospital discharge Accompanying measures: Serum Samples and bronchoscopy samples of patients included into the trial for secondary analysis of inflammatory parameters and potential biomarkers

Description:

The severe form of COVID-19 infection is characterized and marked by severe pneumonia and the Acute Respiratory Distress Syndrome (ARDS). ARDS is characterized by the loss of pulmonary tissue compliance and severe hypoxia. The central pathophysiologic changes of COVID-19+ ARDS are dysregulated inflammation within the alveolar space and altered permeability of the alveolar-capillary barrier. The public health impact of this COVID-19+ ARDS is considerable with a large number of ARDS cases that need to be treated currently on German Intensive Care Units. To date, the associated mortality ranges between 30 to 50%. In the ongoing COVID-19 crisis cases of ARDS will still increase and pose a significant challenge to the German Medical System. Despite the emerging understanding of COVID-19+ ARDS, treatment only remains to be symptomatic using mechanical ventilation, prone positioning and in severe cases of hypoxia extracorporal membrane oxygenation (ECMO). Current evidence generated by clinical trials demonstrates that patients with ARDS should be referred to a specialized center to receive expert treatment. The use of ECMO might have a beneficial effect on overall patient outcome, yet this has not been proven by clinical trials and to date ECMO is recommended as measure of last resort in the current ARDS treatment guidelines. The timing of ECMO placement to relieve hypoxia is an important question for the treating clinician but is not well studied to date. This might also have impact on the long-term functional outcome of patients. In addition, evidence about the role of ECMO in the outcome of COVID-19+ patients might have significant impact on the referral of patients to a specialized center and is important for the treating physician. Therefore, the investigators want to pursue the questions whether early ECMO placement is superior than the placement of ECMO as a rescue measure, and whether this could result in improved overall outcome of patients with COVID-19+ ARDS.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 1, 2022
• Est. primary completion date: April 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• COVID-19positive(+) ARDS as defined according to the Berlin Definition
• ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/ FiO2) =100
• Bilateral opacities consistent with pulmonary edema on frontal chest radiograph
• requirement for positive pressure ventilation via an endotracheal tube or non-invasive ventilation
• no clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mmHg.
• = 7 days from the initiation of mechanical ventilation at the time of randomization. - Patients must be enrolled within 96 hours of onset of ARDS -

Exclusion Criteria:

• COVID-19negative(-) ARDS
• Age less than 18 years
• More than 7 days since initiation of mechanical ventilation
• more than 96 hours since meeting ARDS criteria
• patient, surrogate or physician not committed to full intensive care support.
• pregnancy

Related Conditions & MeSH terms

• ARDS, Human
• COVID-19
• Respiratory Distress Syndrome, Adult

Intervention

Procedure:
• ECMO Implantation
Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.

Locations

Country	Name	City	State
Germany	University Hospital Tuebingen	Tuebingen

Sponsors (4)

Lead Sponsor	Collaborator
University Hospital Tuebingen	RWTH Aachen University, University Hospital Freiburg, University Hospital Muenster

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	28 day all cause mortality	survival in 28-day follow-up period (28 day all cause mortality)	28 Days
Secondary	90 day all cause mortality	90 day all cause mortality	90 days
Secondary	Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days	Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days	day 1-14, 28 and 90
Secondary	duration of mechanical ventilation support	duration of mechanical ventilation support	28 days
Secondary	Ventilator Associated Pneumonia	Number of patients with Ventilator Associated Pneumonia	28 days
Secondary	Bleeding complications	number of blood transfusion units	28 das
Secondary	Acute Renal Failure	Days on real replacement therapy	28 days
Secondary	Discharge Location	Discharge to (home, skilled nursing facility, rehabilitation)	90 days